Andrea Small-Howard

GB Sciences, Inc. (OTCQB: GBLX), a leading plant-inspired, biopharmaceutical R & D development company recently published a study that demonstrates the potential of selected cannabinoids and terpenes to reduce inflammation. It is now developing anti-inflammatory, cannabinoid-based...

Biopharmaceutical research and drug development company, Gb Sciences, Inc. (OTCQB: GBLX), co-published a study in the journal Frontiers in Pharmacology that demonstrates the efficacy of its proprietary cannabinoid-containing, minimum essential mixtures for the treatment of Parkinson's disease....

Gb Sciences, Inc. (OTCQB: GBLX) revealed Tuesday that its sponsored study investigating the effect of nanoparticle encapsulation of three cannabis-based terpenes on their potential efficacy in pain management was published in the International Journal of Pharmaceutics on March 25. For the Gb...

Gb Sciences, Inc. (OTCQB: GBLX) announced Tuesday that it has closed the sale of its last remaining cannabis facility, completing a transition to the biopharmaceutical industry. What Happened Based in Las Vegas, the company reported that management's decision to end all connections...